2022-502869-17-01招募中1 期
FusionVAC22_01: DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 3
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Prof. Dr. Helmut Salih
Scientific
Universitaetsklinikum Tuebingen
研究点 (3)
Loading locations...
相似试验
撤回
1 期
FusionVAC22_01: DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusionfibrolamellar hepatocellular carcinoma2022-502869-17-00Universitaetsklinikum Tuebingen20
招募中
1 期
FusionVAC22_01: DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusiofibrolamellar hepatocellular carcinoma, tumor entities carrying the oncogenic driver fusion DNAJB1-PRKACACTIS2022-502869-17-01niversitaetsklinikum Tuebingen20
进行中（未招募）
1 期
FusionVAC22_01: DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusiotumor entities carrying the oncogenic driver fusion DNAJB1-PRKACA, fibrolamellar hepatocellular carcinomaCTIS2022-502869-17-00niversitaetsklinikum Tuebingen20
招募中
1 期
A study to characterize the pharmacokinetic profile of norucholic acid (NCA) in patients with primary sclerosing cholangitis (PSC)CTIS2023-507027-37-00Dr. Falk Pharma GmbH43
招募中
不适用
jDAPA-PD (jDAPA-PD)jRCT103123062440